With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...
A roundtable discussion reveals how hybrid distributed models could provide a bridge from centralized cell-therapy ...
Astellas Pharma and Yaskawa Electric Corporation have formalized a development deal signed last year that will see the two Japanese companies partner to create an ...
Researchers advance scalable stem-cell bioprocessing with AI-enabled manufacturing for regenerative medicine therapies.
Transition from the manual processes that are performed during the initial research and development (R&D) stage to automated processes for later and commercial stage cell therapy manufacturing can be ...
Pressure to make cell and gene therapies more affordable will force the industry to overcome its reticence and embrace closed production systems, automation, and artificial intelligence (AI). So says, ...
Cellular manufacturing can accommodate high product variety with shorter lead times and less complex scheduling. However, most extant research presents clustering solutions to hypothetical or ...
Automation, decentralized manufacturing, and supportive regulations are helping to surmount technical difficulties in cell and gene therapy manufacturing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results